Portage Biotech 55336VAL4 Bond
| PRTG Stock | USD 4.18 0.03 0.71% |
The Portage Biotech's current Long Term Debt is estimated to increase to about 4.1 M, while Net Debt is forecasted to increase to (4.7 M). . Portage Biotech's financial risk is the risk to Portage Biotech stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.000987 | Current Value 0.000937 | Quarterly Volatility 0.02299506 |
Portage |
Given the importance of Portage Biotech's capital structure, the first step in the capital decision process is for the management of Portage Biotech to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Portage Biotech to issue bonds at a reasonable cost.
| Popular Name | Portage Biotech MPLX LP 52 |
| Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
| Equity ISIN Code | VGG7185A1286 |
| Bond Issue ISIN Code | US55336VAL45 |
| S&P Rating | Others |
| Maturity Date | 1st of March 2047 |
| Issuance Date | 10th of February 2017 |
| Coupon | 5.2 % |
Portage Biotech Outstanding Bond Obligations
| Boeing Co 2196 | US097023DG73 | Details | |
| HSBC Holdings PLC | US404280DR76 | Details | |
| MPLX LP 52 | US55336VAL45 | Details | |
| Morgan Stanley 3591 | US61744YAK47 | Details |
Understaning Portage Biotech Use of Financial Leverage
Portage Biotech's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Portage Biotech's total debt position, including all outstanding debt obligations, and compares it with Portage Biotech's equity. Financial leverage can amplify the potential profits to Portage Biotech's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Portage Biotech is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Net Debt | -5 M | -4.7 M | |
| Short and Long Term Debt Total | 54 K | 51.3 K | |
| Short Term Debt | 36 K | 34.2 K | |
| Long Term Debt | 3.9 M | 4.1 M | |
| Short and Long Term Debt | 135 K | 128.2 K | |
| Net Debt To EBITDA | 0.27 | 0.26 | |
| Long Term Debt To Capitalization | 0.03 | 0.02 | |
| Cash Flow To Debt Ratio | (32.84) | (31.20) |
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out the analysis of Portage Biotech Fundamentals Over Time. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (68.17) | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.